Baillie Gifford & CO Adaptimmune Therapeutics PLC Transaction History
Baillie Gifford & CO
- $126 Billion
- Q2 2024
A detailed history of Baillie Gifford & CO transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Baillie Gifford & CO holds 15,149,203 shares of ADAP stock, worth $11.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,149,203
Previous 15,871,875
4.55%
Holding current value
$11.2 Million
Previous $25.1 Million
40.8%
% of portfolio
0.01%
Previous 0.02%
Shares
29 transactions
Others Institutions Holding ADAP
# of Institutions
81Shares Held
152MCall Options Held
78.5KPut Options Held
36.5K-
Matrix Capital Management Company, LP Waltham, MA39MShares$28.8 Million0.29% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$20.3 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$12.6 Million1.58% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR12.3MShares$9.14 Million0.49% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA10.5MShares$7.78 Million0.53% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $121M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...